CNS Pharma's Cancer Drug Misses Survival Goal But May Offer Fewer Side Effects
CNS Pharmaceuticals' Berubicin trial results show a favorable safety profile with no cardiotoxicity and comparable efficacy ...
Interesting Engineering on MSN5d
New hope for UTI patients as FDA approves first-of-its-kind antibiotic in 30 years
The U.S. Food and Drug Administration (FDA) has approved a new class of antibiotics for treating uncomplicated urinary tract ...
MedPage Today on MSN15d
Mixed Results for Therapeutic Candidates for Platinum-Resistant Ovarian Cancer
Promising therapies for platinum-resistant ovarian cancer produced mixed results in separate trials. The AKT inhibitor afuresertib failed to improve progression-free survival (PFS) when added to ...
MedPage Today on MSN6d
FDA OKs New Option for Uncomplicated UTIs in Women, Girls
The FDA approved oral gepotidacin (Blujepa) for uncomplicated urinary tract infections (UTIs) in women and girls ages 12 ...
Monthly Prescribing Reference12y
Ciprofloxacin Iv Concentrate
The bactericidal action of ciprofloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV (both Type II topoisomerases), which are required for bacterial ...